RVNC Revance Therapeutics Inc

Price (delayed)

$3.58

Market cap

$373.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.64

Enterprise value

$716.54M

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide ...

Highlights
Revance Therapeutics's gross profit has soared by 69% YoY and by 2.4% from the previous quarter
RVNC's revenue has soared by 55% YoY
Revance Therapeutics's debt has increased by 9% YoY

Key stats

What are the main financial stats of RVNC
Market
Shares outstanding
104.45M
Market cap
$373.93M
Enterprise value
$716.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.03
Earnings
Revenue
$236.65M
EBIT
-$296.93M
EBITDA
-$287.87M
Free cash flow
-$220.74M
Per share
EPS
-$3.64
Free cash flow per share
-$2.4
Book value per share
-$1.12
Revenue per share
$2.57
TBVPS
$5.43
Balance sheet
Total assets
$508.12M
Total liabilities
$606.79M
Debt
$475.78M
Equity
-$98.67M
Working capital
$300.78M
Liquidity
Debt to equity
-4.82
Current ratio
5.37
Quick ratio
4.46
Net debt/EBITDA
-1.19
Margins
EBITDA margin
-121.6%
Gross margin
69.1%
Net margin
-134.1%
Operating margin
-129.1%
Efficiency
Return on assets
-60%
Return on equity
N/A
Return on invested capital
-40.3%
Return on capital employed
-67.6%
Return on sales
-125.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVNC stock price

How has the Revance Therapeutics stock price performed over time
Intraday
9.48%
1 week
34.08%
1 month
18.54%
1 year
-84.67%
YTD
-59.27%
QTD
39.3%

Financial performance

How have Revance Therapeutics's revenue and profit performed over time
Revenue
$236.65M
Gross profit
$163.54M
Operating income
-$305.57M
Net income
-$317.35M
Gross margin
69.1%
Net margin
-134.1%
Revance Therapeutics's gross profit has soared by 69% YoY and by 2.4% from the previous quarter
RVNC's revenue has soared by 55% YoY
Revance Therapeutics's net margin has increased by 42% YoY and by 3.1% QoQ
The operating margin is up by 39% year-on-year and by 4.7% since the previous quarter

Growth

What is Revance Therapeutics's growth rate over time

Valuation

What is Revance Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.03
The EPS rose by 22% YoY and by 5% QoQ
Revance Therapeutics's equity has increased by 35% from the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 522.7 and 74% lower than the last 4 quarters average of 5.3
RVNC's revenue has soared by 55% YoY

Efficiency

How efficient is Revance Therapeutics business performance
The ROS rose by 42% YoY and by 3.5% QoQ
The ROIC has grown by 16% YoY and by 6% from the previous quarter
The ROA has decreased by 2.4% YoY

Dividends

What is RVNC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVNC.

Financial health

How did Revance Therapeutics financials performed over time
The total assets is 16% less than the total liabilities
Revance Therapeutics's quick ratio has increased by 41% from the previous quarter and by 20% YoY
The current ratio has grown by 41% from the previous quarter and by 30% YoY
The debt to equity has soared by 71% year-on-year but it has dropped by 53% since the previous quarter
Revance Therapeutics's equity has increased by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.